6,678 trials
Hypotrichosis
Primary: Percentage of Participants Who Are Satisfied or Very Satisfied With Their Eyelashes Overall — 67.4; 7.1 Percentage of participants
Chronic Kidney Disease
Primary: 24-hour Urine Creatinine Excretion Rate — 17.6 mg/24hour/day
Migraine
Primary: Percent Change of Headache Days Compared to Baseline — -13.50; -36.50 percent change of headache days
Osteoarthritis, Knee
Primary: Incidence of Nausea and Vomiting — 24; 40 percentage of participant
Bipolar Disorder
Primary: Primary Measure:Reduction in Depression Symptoms — 16 participants
Age-related Macular Degeneration
Primary: Change in Best-Corrected Visual Acuity (logMAR) From Baseline to Month 12 — -0.18; -0.12 logMAR
Parkinson's Disease
Primary: Incidence of Nausea and/or Vomiting During the Initial Titration of Apokyn® at the Visit on Day 1 — 21; 10; 109; 34 participants — p=0.09
Pulmonary Arterial Hypertension
Primary: Number of Patients Reaching a 6-Minute Walk Test (6MWT) Distance ≥ 380 Meters — 16; 24 participants
Influenza
Primary: Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reaction Following Vaccination With One Dose of Either Fluzone® or Fluzone® High-Dose…
Urinary Bladder, Overactive
Primary: Proportion of Patients Reporting "Moderately" or "Markedly" Improved on the Global Response Assessment (GRA) at 36 Months as Compared to Baseline — .77 Proportion of…
Overactive Bladder
Primary: Frequency of Voids at 12 Weeks — -2.4; -2.5 Voids/day
Insomnia · Primary Insomnia · Psychophysiologic Insomnia
Primary: Sleep Latency (SL) — 1; 2; 3; 0 participants
Hypertension
Primary: Trough Seated Diastolic Blood Pressure (DBP) — -5.5; -11.8 mmHG — p=<0.0001
Blood Clotting
Primary: The Number of Days to First International Normalized Ratio (INR) Within Therapeutic Range — 8.3; 4.7 days
HIV Infections · Hepatitis B
Primary: Hepatitis B Virus (HBV) DNA — 2.4; 0.8 log 10 IU/ml